identified an association between the number of CD8+ PD1+ TCF1+ cells in patients with a favorable response to ICI therapy in hepatocellular carcinoma (54), suggesting a broader applicability across cancer types. This evidence concerns the gene CD8A and hepatocellular carcinoma.